<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01899599</url>
  </required_header>
  <id_info>
    <org_study_id>GEXMab25201</org_study_id>
    <secondary_id>2013-000931-28</secondary_id>
    <nct_id>NCT01899599</nct_id>
  </id_info>
  <brief_title>PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycotope GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glycotope GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy of PankoMab-GEX vs Placebo in maintaining a response to chemotherapy in advanced&#xD;
      ovarian, fallopian tube or primary peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is to evaluate the efficacy of PankoMab-GEX vs Placebo in maintaining response&#xD;
      after 2nd to 5th line of chemotherapy in patients with epithelial ovarian or fallopian tube&#xD;
      or primary peritoneal cancer. Patients must have responded to platinum based chemotherapy in&#xD;
      a previous line, while the response to the most recent Pt-based chemotherapy must not have&#xD;
      lasted more than 12 months. In addition the response between most recent 2 lines of&#xD;
      chemotherapy prior start of study medication must not have lasted more than 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">July 28, 2017</completion_date>
  <primary_completion_date type="Actual">April 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>from baseline till progression of disease or death</time_frame>
    <description>PFS will be determined by radiographic progression based on modified RECIST 1.1 or death of any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of maintenance therapy with single-agent PankoMab-GEX™ compared to placebo in patients with metastatic or recurrent ovarian or fallopian tube carcinoma or primary peritoneal carcinoma.</measure>
    <time_frame>from randomization until end of treatment</time_frame>
    <description>Safety will be determined on the occurrence of infusion-related reactions (IRR), treatment emergent adverse events (TEAE) and treatment emergent serious adverse events (TESAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome</measure>
    <time_frame>from randomization until end of treatment</time_frame>
    <description>To evaluate the quality of life (QoL) and other health and health-economy related outcomes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Ovarian Epithelial Cancer Recurrent</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>PankoMab-GEX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1700mg, i.v., q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PankoMab-GEX</intervention_name>
    <description>start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>PankoMab-GEX</arm_group_label>
    <other_name>Gatipotuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients ≥18 years of age&#xD;
&#xD;
          2. Histologically-confirmed, TA-MUC1-positive, recurrent epithelial ovarian, or&#xD;
             fallopian-tube cancer or primary peritoneal cancer with high-grade (Grade 2 or 3)&#xD;
             serous features or a serous component&#xD;
&#xD;
          3. Availability of tumor tissue samples (slices or block) for immune-histological&#xD;
             confirmation of TA-MUC1 status (tissue samples could also be stored for other further&#xD;
             specified biomarker assessments)&#xD;
&#xD;
          4. Patients were to have received at least 2 lines but not more than 5 lines of&#xD;
             chemotherapy prior to start of maintenance treatment; neo-adjuvant lines did not count&#xD;
             as previous lines of treatment&#xD;
&#xD;
          5. Patients had to have a documented response to or SD following the most recent line of&#xD;
             chemotherapy (any regimen and duration in accordance with local or international&#xD;
             guidelines or within IEC-approved studies) and received the last dose of said&#xD;
             chemotherapy ≤6 weeks prior to randomization (response to prior chemotherapy was&#xD;
             defined as a PR/CR according to radiological response criteria and/or a confirmed&#xD;
             decline in tumor marker CA125 ≥50% from the pre-treatment value for patients who had a&#xD;
             pre-treatment value ≥2 x the upper limit of normal [ULN]; SD was defined as stable&#xD;
             disease according to radiological response criteria with a confirmed lack of increase&#xD;
             in tumor marker CA125 from the pre-treatment value for patients who had a&#xD;
             pre-treatment value ≥2 × ULN and no clinical progression). Prior to randomization,&#xD;
             CA125 had to be below the ULN, or CA125 levels were not to increase &gt;15% within a time&#xD;
             frame &gt;7 days if above the ULN&#xD;
&#xD;
          6. Progression-free interval of ≤12 months immediately preceding the chemotherapy to&#xD;
             which the patient had just responded&#xD;
&#xD;
          7. Sensitive or resistant to the most recent platinum-based chemotherapy preceding the&#xD;
             chemotherapy to which the patient had just responded (sensitivity was thereby defined&#xD;
             as a recurrence of disease &gt;6 to ≤12 months after the end of platinum-based&#xD;
             chemotherapy, and resistantance was defined as a recurrence of disease ≤6 months after&#xD;
             the end of the platinum-based chemotherapy)&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status ≤1&#xD;
&#xD;
          9. Recovered from all chemotherapy-related toxicities to Grade 1 or Grade 0 according to&#xD;
             the NCI-CTCAE Version 4.0, with the exception of alopecia (any grade) and peripheral&#xD;
             neuropathy (≤Grade 2)&#xD;
&#xD;
         10. Adequate bone marrow and hepatic function at Screening:&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  White blood cell count ≥3.0 × 109/L&#xD;
&#xD;
               -  Absolute neutrophil count ≥1.5 × 109/L- Platelet count ≥100 × 109/L&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt;3 × ULN (&lt;5&#xD;
                  × ULN in case of liver metastases)&#xD;
&#xD;
               -  Bilirubin &lt;1.5 × ULN (&lt;3 × ULN in case of liver metastases)&#xD;
&#xD;
               -  Creatinine &lt;1.5 × ULN&#xD;
&#xD;
         11. Any patient with childbearing potential (i.e. not surgically sterile or&#xD;
             post-menopausal for &gt;1 year) had to use highly effective contraceptives with a Pearl&#xD;
             index &lt;1% according to the &quot;Note for guidance on non-clinical safety studies for the&#xD;
             conduct of human clinical trials and marketing authorization for pharmaceuticals&quot;&#xD;
             (CPMP/ICH/286/95) of the European Medicines Agency (EMA). (Although pregnancy was&#xD;
             unlikely to occur in this patient population, any patient with childbearing potential&#xD;
             had to be withdrawn from the study in the event of pregnancy)&#xD;
&#xD;
         12. Life expectancy &gt;3 months&#xD;
&#xD;
         13. Ability and willingness to give written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Refractory to platinum-based chemotherapy (defined as remained progressive or became&#xD;
             progressive under any previous platinum-based regimen)&#xD;
&#xD;
          2. Progression-free interval of &gt;12 months after the most recent antecedent&#xD;
             platinum-based chemotherapy regimen&#xD;
&#xD;
          3. Concomitant anti-tumor therapy or immunotherapy&#xD;
&#xD;
          4. Treatment with monoclonal antibodies or investigational agents ≤30 days before&#xD;
             randomization (prior anti-MUC1 therapy was not permitted at any time)&#xD;
&#xD;
          5. Limited-field radiotherapy ≤30 days before randomization (extensive prior radiotherapy&#xD;
             during or following the last line of chemotherapy was not permitted; radiotherapy&#xD;
             prior to the last line of chemotherapy was permitted)&#xD;
&#xD;
          6. Prior allergic reaction to a monoclonal antibody, Grade 3 IRR or any Grade 4 reaction&#xD;
             to a monoclonal antibody&#xD;
&#xD;
          7. Known sensitivity to any component of the test product&#xD;
&#xD;
          8. Contraindication to the pre-medication used in this study (paracetamol/acetaminophen,&#xD;
             H1 and/or H2 receptor antagonists, or steroids)&#xD;
&#xD;
          9. Clinical evidence of brain metastasis or leptomeningeal involvement&#xD;
&#xD;
         10. Patients with second primary cancer, except adequately treated non-melanoma skin&#xD;
             cancer, curatively treated in-situ cancer of the cervix, ductal carcinoma in situ,&#xD;
             Stage 1 Grade 1 endometrial carcinoma, or other solid tumors including lymphomas&#xD;
             (without bone marrow involvement) curatively treated with no evidence of disease for&#xD;
             ≥5 years&#xD;
&#xD;
         11. Primary or secondary immune deficiency&#xD;
&#xD;
         12. Clinically active infections &gt;Grade 2 using NCI-CTCAE version 4.0&#xD;
&#xD;
         13. Active hepatitis B or C or infection with human immunodeficiency virus (HIV)&#xD;
&#xD;
         14. Myocardial infarction within 6 months prior to Screening&#xD;
&#xD;
         15. Symptomatic congestive heart failure (New York Heart Association Grade 3 or 4),&#xD;
             unstable angina pectoris within 6 months prior to Screening, significant cardiac&#xD;
             arrhythmia or history of stroke or transient ischemic attack within 1 year prior to&#xD;
             Screening&#xD;
&#xD;
         16. Prior or planned major surgery within 30 days prior to randomization and/or incomplete&#xD;
             recovery from prior surgery&#xD;
&#xD;
         17. Concomitant use of systemic steroids, except for inhaled, topical or nasal application&#xD;
             within 30 days prior to randomization (steroids used for pre-medication were&#xD;
             permitted)&#xD;
&#xD;
         18. Active drug or alcohol abuse&#xD;
&#xD;
         19. Any uncontrolled medical condition that could have put the patient at high risk during&#xD;
             treatment with an investigational drug, including unstable diabetes mellitus, vena&#xD;
             cava syndrome, or chronic symptomatic respiratory disease&#xD;
&#xD;
         20. Pregnancy or lactation&#xD;
&#xD;
         21. Legal incompetence, limited legal competence, or detainment in an institution for&#xD;
             official or legal reasons&#xD;
&#xD;
         22. Receipt of any other investigational medicinal product within the last 30 days before&#xD;
             randomization or any previous PankoMab-GEX™ administration&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Ledermann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL Cancer Institute, 90 Tottenham Court Road, London W1T 4TJ, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Kiel</city>
        <zip>24103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Regensburg</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Debrecen</city>
        <zip>4035</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Gdansk</city>
        <zip>80402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Lublin</city>
        <zip>20090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Olsztyn</city>
        <zip>10513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Poznan</city>
        <zip>60569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Rzeszow</city>
        <zip>35242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Brasov</city>
        <zip>500091</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Bucharest</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400058</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Craiova</city>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Oradea</city>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Timisoara</city>
        <zip>300167</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Kazan</city>
        <zip>450029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Oryol</city>
        <zip>302020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>St Petersburg</city>
        <zip>188663</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Volgograd</city>
        <zip>404133</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>London</city>
        <zip>W1T 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 4, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Maintenance Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

